Day: August 1, 2024

Makes Incremental Progress Executing Strategic Initiatives to Accelerate Long-Term Growth Three Veteran Operating and Sales Executives Added to Adventure Team to Support U.S., International and OEM Markets Strategic Review Initiated for PIEPS Snow Safety Brand within the Outdoor Segment SALT LAKE CITY, Aug. 01, 2024 (GLOBE NEWSWIRE) — Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Summary vs. Same Year‐Ago Quarter (adjusted to reflect the reclassification of the Precision Sport segment as discontinued operations)Sales of $56.5 million compared to $57.9 million. Gross margin was 36.1% compared to 39.0%; adjusted gross margin of 37.4% compared to 39.0%. Net...

WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the “Board”) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. The Company has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation,...

Fiscal 2024 Third Quarter Financial Highlights:Outstanding debt reduced by $12.6 million during the quarter 3rd Quarter GAAP EPS of $0.06; non-GAAP adjusted EPS of $0.56 SGK Brand Solutions segment reports sales growth for the quarter Energy storage sales impacted by customer delays Company announces cost reduction initiatives Webcast: Friday, August 2, 2024, 9:00 a.m., (201) 689-8471PITTSBURGH, Aug. 01, 2024 (GLOBE NEWSWIRE) — Matthews International Corporation (NASDAQ GSM: MATW) today announced financial results for its third quarter of fiscal 2024. In discussing the results for the Company’s fiscal 2024 third quarter, Joseph C. Bartolacci, President and Chief Executive Officer, stated: “Our consolidated financial results continue to be underpinned by the strength of our core businesses, particularly from our Memorialization...

MALVERN, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) — CubeSmart (NYSE: CUBE) today announced its operating results for the three and six months ended June 30, 2024. “As expected, we experienced a marginally stronger seasonal uplift in demand during the second quarter and a customer base who continues to be resilient in an uncertain economy,” commented President and Chief Executive Officer Christopher P. Marr. “Our data-driven approach to operations continues to allow us to optimize our performance in the face of changing macro conditions.” Key Highlights for the Second QuarterReported diluted earnings per share (“EPS”) attributable to the Company’s common shareholders of $0.41. Reported funds from operations (“FFO”), as adjusted, per diluted share of $0.64. Same-store (598 stores) net operating income (“NOI”) decreased 1.2% year over...

JACKSONVILLE, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) — Regency Centers Corporation (“Regency Centers”, “Regency” or the “Company”) (Nasdaq: REG) today reported financial and operating results for the period ended June 30, 2024 and provided updated 2024 earnings guidance. For the three months ended June 30, 2024 and 2023, Net Income Attributable to Common Shareholders was $0.54 per diluted share and $0.51 per diluted share, respectively. Second Quarter HighlightsReported Nareit FFO of $1.06 per diluted share and Core Operating Earnings of $1.02 per diluted share Raised 2024 Nareit FFO guidance to a range of $4.21 to $4.25 per diluted share and 2024 Core Operating Earnings guidance to a range of $4.06 to $4.10 per diluted share The midpoint of 2024 Core Operating Earnings guidance represents approximately 4% year-over-year growth,...

Raises 2024 Revenue Guidance Midpoint to $5.15 Billion; Revises 2024 Adjusted EBITDA Guidance Midpoint from $500 Million to $380 Million; Continues to Expect 2025 Adjusted EBITDA in the Range of $900 Million to $1.0 Billion BOSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today announced results for the second quarter of 2024 and that its Board of Directors authorized the repurchase of an aggregate of up to $1.0 billion of its Class A common stock. The Company also posted a second quarter 2024 business update and an earnings presentation on the Investor Relations section of its website at investors.draftkings.com. Second Quarter 2024 HighlightsFor the three months ended June 30, 2024, DraftKings reported revenue of $1,104 million, an increase of $230 million, or 26%, compared...

BETHESDA, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) — Elme Communities (the “Company”) (NYSE: ELME), a multifamily REIT with communities in the Washington, DC metro area and the Atlanta metro area, reported financial and operating results today for the quarter ended June 30, 2024: Financial ResultsNet loss was $3.5 million, or $0.04 per diluted share NAREIT FFO was $20.4 million, or $0.23 per diluted share Core FFO was $20.5 million, or $0.23 per diluted share Net Operating Income (NOI) was $38.1 millionOperational HighlightsSame-store multifamily NOI increased by 1.3% compared to the prior year period Effective blended Lease Rate Growth increased to 3.2% for our Same-Store Portfolio during the quarter, comprised of effective new Lease Rate Growth of 0.2% and effective renewal Lease Rate Growth of 5.4% Average Effective Monthly...

– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial evaluating petosemtamab monotherapy in 2/3L HNSCC, phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in 2L mCRC, and phase 2 trial evaluating MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC – Based on the Company’s current operating plan, existing cash, cash equivalents, including successful public offering raising $460M gross proceeds, and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...